drugset / Trial / NCT02145689

Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

NCT02145689 ↗

Phase 3 Withdrawn Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a long-term safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.

Timeline

Start
2014-08
Primary completion
2017-05
Completion
2017-05

Outcome

Outcome not reported

Stopped (Enrollment): “The study was withdrawn prior to enrollment due to corporate decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Intramuscular

Indications